155 related articles for article (PubMed ID: 22594760)
1. Pharmacogenomics of third-generation aromatase inhibitors.
Turkistani A; Marsh S
Expert Opin Pharmacother; 2012 Jun; 13(9):1299-307. PubMed ID: 22594760
[TBL] [Abstract][Full Text] [Related]
2. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
3. Aromatase inhibitors and breast cancer prevention.
Litton JK; Arun BK; Brown PH; Hortobagyi GN
Expert Opin Pharmacother; 2012 Feb; 13(3):325-31. PubMed ID: 22242911
[TBL] [Abstract][Full Text] [Related]
4. Current role and safety profile of aromatase inhibitors in early breast cancer.
Tomao F; Spinelli G; Vici P; Pisanelli GC; Cascialli G; Frati L; Panici PB; Tomao S
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1253-63. PubMed ID: 21916579
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of aromatase inhibitors.
Hadfield KD; Newman WG
Pharmacogenomics; 2012 Apr; 13(6):699-707. PubMed ID: 22515612
[TBL] [Abstract][Full Text] [Related]
6. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
7. Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.
Miron L; Negură L; Peptanariu D; Marinca M
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):997-1004. PubMed ID: 23700878
[TBL] [Abstract][Full Text] [Related]
8. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
Ingle JN
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
[TBL] [Abstract][Full Text] [Related]
9. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Fontein DB; Houtsma D; Nortier JW; Baak-Pablo RF; Kranenbarg EM; van der Straaten TR; Putter H; Seynaeve C; Gelderblom H; van de Velde CJ; Guchelaar HJ
Breast Cancer Res Treat; 2014 Apr; 144(3):599-606. PubMed ID: 24590773
[TBL] [Abstract][Full Text] [Related]
10. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitors in the treatment of early and advanced breast cancer.
Joensuu H; Ejlertsen B; Lønning PE; Rutqvist LE
Acta Oncol; 2005; 44(1):23-31. PubMed ID: 15848903
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Cairns J; Ingle JN; Dudenkov TM; Kalari KR; Carlson EE; Na J; Buzdar AU; Robson ME; Ellis MJ; Goss PE; Shepherd LE; Goodnature B; Goetz MP; Weinshilboum RM; Li H; Bari MG; Wang L
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32701512
[TBL] [Abstract][Full Text] [Related]
13. Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.
Hertz DL; Henry NL; Rae JM
Pharmacogenomics; 2017 Apr; 18(5):481-499. PubMed ID: 28346074
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors in breast cancer therapy.
Brueggemeier RW
Expert Rev Anticancer Ther; 2002 Apr; 2(2):181-91. PubMed ID: 12113240
[TBL] [Abstract][Full Text] [Related]
15. Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
Santa-Maria CA; Blackford A; Nguyen AT; Skaar TC; Philips S; Oesterreich S; Rae JM; Desta Z; Robarge J; Henry NL; Storniolo AM; Hayes DF; Blumenthal RS; Ouyang P; Post WS; Flockhart DA; Stearns V;
Clin Cancer Res; 2016 Mar; 22(6):1395-402. PubMed ID: 26463708
[TBL] [Abstract][Full Text] [Related]
16. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
17. Optimal sequence of hormonotherapy in advanced breast cancer.
Bertelli G; Paridaens R
Curr Opin Oncol; 2006 Nov; 18(6):572-7. PubMed ID: 16988577
[TBL] [Abstract][Full Text] [Related]
18. Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.
Jhaveri K; Halperin P; Shin SJ; Vahdat L
Breast Cancer Res Treat; 2007 Dec; 106(3):315-8. PubMed ID: 17972174
[TBL] [Abstract][Full Text] [Related]
19. The evolving role of aromatase inhibitors in breast cancer.
Mokbel K
Int J Clin Oncol; 2002 Oct; 7(5):279-83. PubMed ID: 12402060
[TBL] [Abstract][Full Text] [Related]
20. Are all aromatase inhibitors the same? A review of the current evidence.
Jänicke F
Breast; 2004 Dec; 13 Suppl 1():S10-8. PubMed ID: 15585378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
